about
Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferretsHeterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates.Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine.Combination DNA plus protein HIV vaccines.Clostridium difficile infections in China.DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China.Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates.The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteersCross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.Heterologous prime-boost vaccination.Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1)DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.DNA immunization.DNA Immunization for HIV Vaccine Development.Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China.Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase.SIV DNA vaccine trial in macaques: post-challenge necropsy in vaccine and control groups.Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B.Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague.Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate.Construction and evaluation of replication-defective recombinant optimized triosephosphate isomerase adenoviral vaccination in Schistosoma japonicum challenged mice.Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.Profile of HIV-1 infected patients from an AIDS clinic in Beijing from 2007-2008.Profiles of B and T cell immune responses elicited by different forms of the hepatitis B virus surface antigen.Human versus HIV: round 2 defeat in AIDS vaccine development.Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera.Vaccinology: precisely tuned antibodies nab HIV.Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.Antigen engineering in DNA immunization.Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.Using DNA Immunization to Elicit Monoclonal Antibodies in Mice, Rabbits, and Humans
P50
Q28742787-F4FF2F2E-4F34-4D70-858A-26604AC466A7Q30369828-11882B36-014C-415B-BDDF-EA656EEEC781Q30379200-45ED5A64-E8AF-4CA6-9D1B-1E12669A6FC7Q33698142-A24220CE-5DBD-483F-9059-1A42940954AAQ33749827-5E8F89DD-A623-4849-9A78-7106CA3A41A1Q33759392-ECE61F61-5EEB-40CB-A373-B75BD2DD8523Q34128200-6BB50F52-B529-47C5-9823-65885F79B746Q34444535-1B9F7D77-0C43-4DA1-B6D7-F3C314B666C3Q35826610-F9B14C4F-A056-402A-8190-E701CE1BBDA1Q36614954-B1DB208D-A42D-47A3-8AC4-D180EC1F5BB1Q36681933-DAAB12DA-055F-4CAB-A597-14750F82E5A7Q36694841-CD01115B-2795-4FEF-9A43-A9A548F5549DQ36694846-AEDEC0A8-8352-4792-B9C4-CF57532E5A51Q36945335-0E551C51-5CCF-4E39-977E-54BD5F6AAF6EQ37329415-BE4BB218-069E-44F0-BF4E-FF7141413E43Q37509586-F4ACD378-B76F-49E8-A64E-12E8AF60E3F3Q37530471-D264A00C-5581-4A4B-AD58-E8B39190D71EQ37530479-E1AB6D2A-FFCA-459A-8D53-DE467B5FBF99Q37576264-F611AE8F-9A54-4079-B60B-F6E0A050A764Q38581981-F4D88F5F-93AD-4768-B88D-AE5338BE9B13Q39314707-A0744748-58C6-4A96-BAFF-D524E7258E71Q39334333-06526D09-AAD5-421A-B783-D55ACC3C1A65Q39803243-22A675F8-2FB8-4AB3-8B30-C45BAE43AC73Q40892268-3B94928A-3675-4AAF-81A2-9CF3E0B9FF82Q41222915-9229CB05-1A6B-4599-A1E5-0037E1F1F26AQ41346392-056B5C54-7958-40AE-A656-6A1740D43E21Q41461629-9C8A337E-AEDC-4F72-BD27-D87A8044937EQ42054413-7EAB069C-7CAD-411A-A942-38BDC80E5FACQ42233884-05521273-6F55-433B-A73F-9F46503F1D66Q42554027-AE9C74E7-18DE-4BC0-AB38-EBA7546E64DFQ43680776-BA9A12A4-9D70-4AEF-A9A6-F3CD92480007Q44014135-C7FD6720-3DFC-4EAF-A757-FFB9EAE5D0B3Q44838793-D93BDBBF-E40E-476C-9FB1-8713B24502B3Q45129797-CC411749-A9D5-40EA-A6F9-A4E13498D687Q45138465-52B93FA4-D63C-409C-BA33-2D7893EC9A77Q45417687-7D4FAE19-054F-4197-B900-12849DBEF62BQ47768173-47129FDA-457E-4A27-9445-13C458A85D02Q47805031-D65C729B-610D-423D-9EBE-AF52D548BA81Q47878348-657AB850-1E8A-4041-B967-8064246B4F67Q57164103-7507CE96-1307-4564-B1BB-FFF372A4DA13
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Shan Lu
@ast
Shan Lu
@en
Shan Lu
@es
Shan Lu
@sl
type
label
Shan Lu
@ast
Shan Lu
@en
Shan Lu
@es
Shan Lu
@sl
prefLabel
Shan Lu
@ast
Shan Lu
@en
Shan Lu
@es
Shan Lu
@sl
P106
P31
P496
0000-0002-8417-7588